Back to top

Image: Shutterstock

The Zacks Analyst Blog Highlights: Anheuser-Busch InBev, Gilead Sciences, Canadian National Railway, Stryker Corp and Goldman Sachs

Read MoreHide Full Article

For Immediate Release

Chicago, IL – September 28, 2020 – announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Anheuser-Busch InBev SA/NV (BUD - Free Report) , Gilead Sciences, Inc. (GILD - Free Report) , Canadian National Railway Company (CNI - Free Report) , Stryker Corporation (SYK - Free Report) and The Goldman Sachs Group, Inc. (GS - Free Report) .

Here are highlights from Friday’s Analyst Blog:

Top Stock Reports for Anheuser-Busch, Gilead and Canadian National

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Anheuser-Busch InBev, Gilead Sciences and Canadian National Railway. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Anheuser-Busch shares have underperformed the Zacks Alcoholic Beverages industry in the year to date period (-35.5% vs. -23.4%). The Zacks analyst believes that gradual reopening of the on-premise channels across many countries led to improved volume trends on a month-to-month basis for AB InBev.

Though overall volume declined year over year in the quarter, volume trends improved on a month-to-month basis. Further, strength in the off-premise channel and premium brands remain encouraging. Driven by these trends, it reported better-than-expected top and bottom line results in second-quarter 2020.

Additionally, the company’s investment behind B2B platforms, e-commerce channels and digital marketing have accelerated in the past few months, which is likely to aid growth in the coming quarters. However, the company’s second-quarter top and bottom lines declined year over year driven by significant impacts of the pandemic.

(You can read the full research report on Anheuser-Busch here >>>)

Shares of Gilead have lost -1.6% over the past year against the Zacks Biomedical and Genetics industry’s rise of +15.9%. The Zacks analyst believes that Gilead's strong HIV franchise should help the company maintain its momentum. Newly launched products should continue to perform well, thereby driving the top-line growth.

The ongoing pandemic impacted Gilead’s sales for both the HCV and HIV franchises, which caused fewer healthcare provider visits and screenings. HIV sales are impacted by lower sales volume of Truvada. Meanwhile, the company lifted its annual guidance probably to account for sales from its antiviral drug remdesivir for COVID-19.

Gilead is also seeing early signs of recovery from this impact and expects a full rebound by the second half. Increase in demand for remdesivir should boost the top line as the pandemic continues to impact more and more people globally. Yescarta too is picking up gradually. However, the prospects of remdesivir will be hit once a vaccine is out.

(You can read the full research report on Gilead here >>>)

Canadian National’s shares have gained +36.3% over the past six months against the Zacks Rail industry’s rise of +37.3%. The Zacks analyst believes that Canadian National is being aided by shipments of higher volumes of grains.

The company moved a record 15 million metric tonnes of Canadian grain in the first half of 2020. The company's buyout of TransX is another positive and has contributed to its supply chain and intermodal businesses across North America. The company’s efforts to continue paying dividends to shareholders despite adversities are an added boon.

Strong free-cash flow generation (up 97.8% in first-half 2020) supports such activities. However, decline in freight revenues, mainly due to coronavirus-led weak volumes, is concerning. Deterioration in the operating ratio due to high operating expenses is an added bane. The company's liquidity position is also worrisome.

(You can read the full research report on Canadian National here >>>)

Other noteworthy reports we are featuring today include Stryker and Goldman Sachs.

Biggest Tech Breakthrough in a Generation

Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.

A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.

See 8 breakthrough stocks now>>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339                                                                        


Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit information about the performance numbers displayed in this press release.